Australian AI specialists raise nearly $20 million

Harrison.ai, a Sydney, Australia-based healthcare company focused on AI technologies, has completed a funding round worth $19.9 million (A$29 million).

Blackbird Ventures led the round, with additional contributions coming from Horizons Ventures, Skip Capital and Ramsay Healthcare. The money is expected to go toward hiring more employees to focus on data science and software engineering, according to a prepared statement. Funding will also be used to develop new AI applications related to “radiology, pathology and hospital operation.”

“I’m excited to be able to use my AI and medical background to help many thousands, potentially millions, of patients to achieve better healthcare outcomes faster than I ever could have by treating patients individually,” Aengus Tran, MD, Harrison.ai co-founder, said in the statement. “Wearing the dual hat of a clinician and an AI engineer translates into clinically sound designs and technically robust solutions to benefit patients.”

“Australia leads the world in many areas of healthcare,” Dimitry Tran, Harrison.ai co-founder, said in the same statement. “We have home-grown organizations that went on to become the world's largest in their domains such as Ramsay Health Care in hospital, Virtus Health in fertility and I-MED in radiology. This presents a great opportunity for technology development and global distribution. At Harrison.ai, a key part of our strategy moving forward is to collaborate with such organizations to develop AI-as-medical-device solutions that improve efficiency, accuracy and safety, ultimately enhancing patient outcomes.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.